Screener
Eikon Therapeutics, Inc. EIKN Q3 2026 earnings
Reported November 12, 2026 · Before market open
EPS-$1.59Beat by $0.11
EPS estimate-$1.70
“At the 2026 ESMO Congress, we presented updated results from TeLuRide-005, providing additional evidence of durable anti-tumor activity for EIK1001 in combination with standard-of-care therapy in squamous NSCLC, building on earlier data in non-squamous NSCLC that we shared at ASCO. We also presented encouraging activity and tolerability data across our selective PARP1 inhibitor programs, supporting their continued development, alongside initial findings from our WRN inhibitor program. Taken together, these findings demonstrate the breadth of our clinical portfolio and reflect our broader mission at Eikon to translate rigorous science into innovative medicines with the potential to address important unmet needs in cancer therapy.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Eikon Therapeutics, Inc. report Q3 2026 earnings?
- Eikon Therapeutics, Inc. (EIKN) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Eikon Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Eikon Therapeutics, Inc. reported eps of $-1.59 for Q3 2026.
- Did Eikon Therapeutics, Inc. beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-1.70 by $0.11.
- Where can I find Eikon Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-456794) and the 10-Q periodic report (0001193125-26-456835) directly on SEC EDGAR. The filing index links above go to sec.gov.
